Paying users zone. Data is covered by hidden.

  • Get 1 month access to Regeneron Pharmaceuticals Inc. for $13.99, or

  • get full access to entire website for at least 3 months from $49.99.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey

Microsoft Excel LibreOffice Calc

Regeneron Pharmaceuticals Inc. (REGN)


Analysis of Inventory

Difficulty: Advanced


Inventory Accounting Policy

Inventories are stated at the lower of cost or estimated realizable value. Regeneron determines the cost of inventory using the first-in, first-out, or FIFO, method.

Regeneron capitalizes inventory costs associated with Regeneron’s products prior to regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed. The determination to capitalize inventory costs is based on various factors, including status and expectations of the regulatory approval process, any known safety or efficacy concerns, potential labeling restrictions, and any other impediments to obtaining regulatory approval.

Regeneron periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value, and writes-down such inventories as appropriate. In addition, Regeneron’s products are subject to strict quality control and monitoring which Regeneron performs throughout the manufacturing process. If certain batches or units of product no longer meet quality specifications or become obsolete due to expiration, Regeneron records a charge to write down such unmarketable inventory to its estimated realizable value.

Source: 10-K (filing date: 2019-02-07).


Inventory Disclosure

Regeneron Pharmaceuticals Inc., Statement of Financial Position, Inventory

USD $ in thousands

Microsoft Excel LibreOffice Calc
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Raw materials hidden hidden hidden hidden hidden
Work-in-process hidden hidden hidden hidden hidden
Finished goods hidden hidden hidden hidden hidden
Deferred costs hidden hidden hidden hidden hidden
Inventories hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-12).

Item Description The company
Inventories Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Regeneron Pharmaceuticals Inc.’s inventories increased from 2016 to 2017 and from 2017 to 2018.